<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02318303</url>
  </required_header>
  <id_info>
    <org_study_id>GPL/CT/2014/004/II</org_study_id>
    <secondary_id>IND Number: 123164</secondary_id>
    <secondary_id>Study Number (GSP 301-201)</secondary_id>
    <nct_id>NCT02318303</nct_id>
  </id_info>
  <brief_title>To Study GSP 301 in Patients With Seasonal Allergic Rhinitis</brief_title>
  <official_title>A Double-blind, Randomized, Parallel-group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Two Different Strengths and Regimens of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators), in Subjects (12 Years of Age and Older) With Seasonal Allergic Rhinitis (SAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in
      treatment of seasonal allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in rTNSS From Baseline to End of Treatment</measure>
    <time_frame>14 days</time_frame>
    <description>Subjects were asked to assess rTNSS (reflective Total Nasal Symptom Score), ie, an evaluation of symptom severity over the past 12 hours prior to the recording of the score. The TNSS was defined as the sum of the subject-reported symptom severity scores for the following four nasal symptoms, recorded by each subject in the diary: rhinorrhea, sneezing, nasal congestion, nasal itching.
The total rTNSS scores for all four symptoms (i.e, the lowest possible score (0) and the highest possible score (12).)
The severity scale for each symptom evaluation was defined as follows:
0 = absent (no sign/symptom evident)
1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated)
2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable)
3 = severe (sign/symptom that is hard to tolerate [i.e., causes interference with activities of daily living and/or sleeping])</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">1111</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>GSP 301 Placebo NS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GSP 301-1 NS (QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GSP 301-2 NS (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olopatadine HCl-1 NS (QD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olopatadine HCl-2 NS (BID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone Furoate-1 NS (QD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone Furoate-2 NS (BID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP 301-1 NS (QD)</intervention_name>
    <description>GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril</description>
    <arm_group_label>GSP 301-1 NS (QD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP 301-2 NS (BID)</intervention_name>
    <description>GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril</description>
    <arm_group_label>GSP 301-2 NS (BID)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP 301 Placebo NS</intervention_name>
    <description>GSP 301 placebo NS administered as 2 sprays/nostril</description>
    <arm_group_label>GSP 301 Placebo NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine HCl-1 NS (QD)</intervention_name>
    <description>Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril</description>
    <arm_group_label>Olopatadine HCl-1 NS (QD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine HCl-2 NS (BID)</intervention_name>
    <description>Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril</description>
    <arm_group_label>Olopatadine HCl-2 NS (BID)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate-1 NS (QD)</intervention_name>
    <description>Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril</description>
    <arm_group_label>Mometasone Furoate-1 NS (QD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate-2 NS (BID)</intervention_name>
    <description>Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril</description>
    <arm_group_label>Mometasone Furoate-2 NS (BID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Aged ≥12 years and older inclusive of either sex.

          2. Documented clinical history of SAR (for at least 2 years preceding the Screening Visit
             [Visit 1]) with exacerbations (clinical evidence of active symptoms) during the study
             season for the mountain cedar pollen

          3. A 12-hour reflective TNSS ≥ 8 out of a possible 12 and a congestion score of ≥ 2 for
             the AM assessment at the Screening Visit (Visit 1).

        Key Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Plans to travel outside the known pollen area for the investigative site for &gt; 24
             hours during the last 7 days of run in period.

          3. History of nasal polyps of other clinically significant respiratory tract
             malformations, recent nasal biopsy, nasal trauma (such as nasal piercing) or surgery,
             atopic dermatitis or rhinitis medicamentosa.

          4. History of anaphylaxis and/or other severe local reaction(s) to skin testing.

          5. History of positive test for HIV, Hepatitis B or Hepatitis C infection.

          6. Documented evidence of acute or significant chronic sinusitis or chronic purulent
             postnasal drip.

          7. Subjects with an active pulmonary disorder or infection.

          8. Subjects with posterior subcapsular cataracts or glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudeesh Tantry, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glenmark Investigational Site 10</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 5</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 6</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 2</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 7</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 3</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 4</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 8</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 9</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenmark Investigational Site 1</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2014</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>May 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2017</results_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 10 sites in the US.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GSP 301 Placebo NS</title>
          <description>GSP 301 placebo NS administered as 2 sprays/nostril</description>
        </group>
        <group group_id="P2">
          <title>GSP 301-1 NS (QD)</title>
          <description>GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril</description>
        </group>
        <group group_id="P3">
          <title>Mometasone Furoate-1 NS (QD)</title>
          <description>Mometasone furoate-1 NS (50 μg) administered as 2 sprays/nostril</description>
        </group>
        <group group_id="P4">
          <title>Olopatadine HCl-1 NS (QD)</title>
          <description>Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril</description>
        </group>
        <group group_id="P5">
          <title>GSP 301-2 NS (BID)</title>
          <description>GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril</description>
        </group>
        <group group_id="P6">
          <title>Mometasone Furoate-2 NS (BID)</title>
          <description>Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril</description>
        </group>
        <group group_id="P7">
          <title>Olopatadine HCl-2 NS (BID)</title>
          <description>Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="158"/>
                <participants group_id="P5" count="157"/>
                <participants group_id="P6" count="159"/>
                <participants group_id="P7" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="157"/>
                <participants group_id="P4" count="155"/>
                <participants group_id="P5" count="152"/>
                <participants group_id="P6" count="153"/>
                <participants group_id="P7" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSP 301 Placebo NS</title>
          <description>GSP 301 placebo NS administered as 2 sprays/nostril</description>
        </group>
        <group group_id="B2">
          <title>GSP 301-1 NS (QD)</title>
          <description>GSP 301-1 NS administered as 2 sprays/nostril</description>
        </group>
        <group group_id="B3">
          <title>Mometasone Furoate-1 NS (QD)</title>
          <description>Mometasone furoate-1 NS administered as 2 sprays/nostril</description>
        </group>
        <group group_id="B4">
          <title>Olopatadine HCl-1 NS (QD)</title>
          <description>Olopatadine HCl-1 NS administered as 2 sprays/nostril</description>
        </group>
        <group group_id="B5">
          <title>GSP 301-2 NS (BID)</title>
          <description>GSP 301-2 NS administered as 2 sprays/nostril</description>
        </group>
        <group group_id="B6">
          <title>Mometasone Furoate-2 NS (BID)</title>
          <description>Mometasone furoate-2 NS administered as 2 sprays/nostril</description>
        </group>
        <group group_id="B7">
          <title>Olopatadine HCl-2 NS (BID)</title>
          <description>Olopatadine HCl-2 NS administered as 2 sprays/nostril</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
            <count group_id="B2" value="158"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="158"/>
            <count group_id="B5" value="157"/>
            <count group_id="B6" value="159"/>
            <count group_id="B7" value="160"/>
            <count group_id="B8" value="1111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.35" spread="14.951"/>
                    <measurement group_id="B2" value="43.83" spread="13.609"/>
                    <measurement group_id="B3" value="44.40" spread="14.312"/>
                    <measurement group_id="B4" value="41.90" spread="12.478"/>
                    <measurement group_id="B5" value="43.44" spread="14.128"/>
                    <measurement group_id="B6" value="44.58" spread="13.698"/>
                    <measurement group_id="B7" value="43.49" spread="13.868"/>
                    <measurement group_id="B8" value="43.86" spread="13.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="111"/>
                    <measurement group_id="B6" value="96"/>
                    <measurement group_id="B7" value="101"/>
                    <measurement group_id="B8" value="740"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="63"/>
                    <measurement group_id="B7" value="59"/>
                    <measurement group_id="B8" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in rTNSS From Baseline to End of Treatment</title>
        <description>Subjects were asked to assess rTNSS (reflective Total Nasal Symptom Score), ie, an evaluation of symptom severity over the past 12 hours prior to the recording of the score. The TNSS was defined as the sum of the subject-reported symptom severity scores for the following four nasal symptoms, recorded by each subject in the diary: rhinorrhea, sneezing, nasal congestion, nasal itching.
The total rTNSS scores for all four symptoms (i.e, the lowest possible score (0) and the highest possible score (12).)
The severity scale for each symptom evaluation was defined as follows:
0 = absent (no sign/symptom evident)
1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated)
2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable)
3 = severe (sign/symptom that is hard to tolerate [i.e., causes interference with activities of daily living and/or sleeping])</description>
        <time_frame>14 days</time_frame>
        <population>The full analysis set (FAS) included all randomized subjects who received at least one dose of randomized study medication and had at least one post-baseline primary efficacy assessment. This was the primary analysis set for efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>GSP 301 Placebo</title>
            <description>GSP 301 placebo NS administered as 2 sprays/nostril</description>
          </group>
          <group group_id="O2">
            <title>GSP 301-1 NS (QD)</title>
            <description>GSP 301-1 NS (QD) administered as 2 sprays/nostril</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate-1 NS (QD)</title>
            <description>Mometasone furoate-1 NS (QD) administered as 2 sprays/nostril</description>
          </group>
          <group group_id="O4">
            <title>Olopatadine HCl-1 NS (QD)</title>
            <description>Olopatadine HCl-1 NS (QD) administered as 2 sprays/nostril</description>
          </group>
          <group group_id="O5">
            <title>GSP 301-2 NS (BID)</title>
            <description>GSP 301-2 NS (BID) administered as 2 sprays/nostril</description>
          </group>
          <group group_id="O6">
            <title>Mometasone Furoate-2 NS (BID)</title>
            <description>Mometasone furoate-2 NS (BID) administered as 2 sprays/nostril</description>
          </group>
          <group group_id="O7">
            <title>Olopatadine HCl-2 NS (BID)</title>
            <description>Olopatadine HCl-2 NS (BID) administered as 2 sprays/nostril</description>
          </group>
        </group_list>
        <measure>
          <title>Change in rTNSS From Baseline to End of Treatment</title>
          <description>Subjects were asked to assess rTNSS (reflective Total Nasal Symptom Score), ie, an evaluation of symptom severity over the past 12 hours prior to the recording of the score. The TNSS was defined as the sum of the subject-reported symptom severity scores for the following four nasal symptoms, recorded by each subject in the diary: rhinorrhea, sneezing, nasal congestion, nasal itching.
The total rTNSS scores for all four symptoms (i.e, the lowest possible score (0) and the highest possible score (12).)
The severity scale for each symptom evaluation was defined as follows:
0 = absent (no sign/symptom evident)
1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated)
2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable)
3 = severe (sign/symptom that is hard to tolerate [i.e., causes interference with activities of daily living and/or sleeping])</description>
          <population>The full analysis set (FAS) included all randomized subjects who received at least one dose of randomized study medication and had at least one post-baseline primary efficacy assessment. This was the primary analysis set for efficacy analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="158"/>
                <count group_id="O5" value="157"/>
                <count group_id="O6" value="159"/>
                <count group_id="O7" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="1.18"/>
                    <measurement group_id="O2" value="10.4" spread="1.24"/>
                    <measurement group_id="O3" value="10.4" spread="1.30"/>
                    <measurement group_id="O4" value="10.3" spread="1.26"/>
                    <measurement group_id="O5" value="10.4" spread="1.19"/>
                    <measurement group_id="O6" value="10.5" spread="1.13"/>
                    <measurement group_id="O7" value="10.3" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.00"/>
                    <measurement group_id="O2" value="-2.5" spread="2.52"/>
                    <measurement group_id="O3" value="-2.2" spread="2.68"/>
                    <measurement group_id="O4" value="-1.7" spread="2.09"/>
                    <measurement group_id="O5" value="-2.6" spread="2.56"/>
                    <measurement group_id="O6" value="-1.9" spread="1.88"/>
                    <measurement group_id="O7" value="-2.1" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs were collected from the time of signing the informed consent form until the follow-up contact</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSP 301 Placebo NS</title>
          <description>GSP 301 placebo NS administered as 2 sprays/nostril</description>
        </group>
        <group group_id="E2">
          <title>GSP 301-1 NS (QD)</title>
          <description>GSP 301-1 NS (QD) administered as 2 sprays/nostril</description>
        </group>
        <group group_id="E3">
          <title>Mometasone Furoate-1 NS (QD)</title>
          <description>Mometasone furoate-1 NS (QD) administered as 2 sprays/nostril</description>
        </group>
        <group group_id="E4">
          <title>Olopatadine HCl-1 NS (QD)</title>
          <description>Olopatadine HCl-1 NS (QD) administered as 2 sprays/nostril</description>
        </group>
        <group group_id="E5">
          <title>GSP 301-2 NS (BID)</title>
          <description>GSP 301-2 NS (BID) administered as 2 sprays/nostril.</description>
        </group>
        <group group_id="E6">
          <title>Mometasone Furoate-2 NS (BID)</title>
          <description>Mometasone furoate-2 NS (BID) administered as 2 sprays/nostril</description>
        </group>
        <group group_id="E7">
          <title>Olopatadine HCl-2 NS (BID)</title>
          <description>Olopatadine HCl-2 NS (BID) administered as 2 sprays/nostril</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal ulcer and Gastritis</sub_title>
                <description>There were two SAEs (gastrointestinal ulcer and gastritis) reported both in the same subject.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Per the agreement, Sponsor reserves the right for publishing trial results and the Investigator cannot publish without written consent from the CRO/ Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cathy Tyrrell</name_or_title>
      <organization>Glenmark Pharmaceuticals Ltd</organization>
      <phone>91 2267720000</phone>
      <email>clinicaltrialsdisclosuredesk@glenmarkpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

